Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05364073
Title Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors ArriVent BioPharma, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | CAN | AUS

Facility Status City State Zip Country Details
ArriVent Investigative Site Prescott Arizona 86301 United States Details
ArriVent Investigative Site Sacramento California 95817 United States Details
ArriVent Investigative Site Celebration Florida 34747 United States Details
ArriVent Investigative Site Detroit Michigan 48202 United States Details
ArriVent Investigative Site Houston Texas 77030 United States Details
ArriVent Investigative Site Fairfax Virginia 22031 United States Details
ArriVent Investigative Site Blacktown New South Wales 2148 Australia Details
ArriVent Investigative Site St Leonards New South Wales 2065 Australia Details
ArriVent Investigative Site Heidelberg Victoria 3084 Australia Details
Arrivent Investigative Site Edmonton T6G 1Z2 Canada Details
Arrivent Investigative Site Toronto M5G 2M9 Canada Details
Allist Investigative Site Hefei Anhui 230001 China Details
Allist Investigative Site Beijing Beijing 101119 China Details
Allist Investigative Site Chaoyang Beijing 100021 China Details
Allist Investigative Site Chongqing Chongqing 400030 China Details
Allist Investigative Site Guiyang Guizhou 550004 China Details
Allist Investigative Site Harbin Heilongjiang 150081 China Details
Allist Investigative Site Zhengzhou Henan 450003 China Details
Allist Investigative Site Zhengzhou Henan 450052 China Details
Allist Investigative Site Wuhan Hubei 430022 China Details
Allist Investigative Site XuZhou Jiangsu 221000 China Details
Allist Investigative Site Nanchang Jianxi 330008 China Details
Allist Investigative Site Changchun Jilin 130012 China Details
Allist Investigative Site Jinan Shan Dong 250021 China Details
Allist Investigative Site Jinan Shandong 250117 China Details
Allist Investigative Site Shanghai Shanghai 200030 China Details
Allist Investigative Site Taiyuan Shanxi 030013 China Details
ArriVent Investigative Site Lyon 69373 France Details
Arrivent Investigative Site Toulouse 31059 France Details
Arrivent Investigative Site Villejuif 94800 France Details
ArriVent Investigative Site Medolla 47014 Italy Details
ArriVent Investigative Site Chiba-Shi Chiba 260-0013 Japan Details
Arrivent Investigative Site Ōsaka-sayama Osaka 589-8511 Japan Details
Arrivent Investigative Site Chuo Tokyo 104-0045 Japan Details
Arrivent Investigative Site Koto-Ku Tokyo 135-8550 Japan Details
Arrivent Investigative Site Gwangju 61469 Korea, Republic of Details
Arrivent Investigative Site Seoul 2447 Korea, Republic of Details
Arrivent Investigative Site Amsterdam Noord-Holland 1066 CX Netherlands Details
ArriVent Investigative Site Barcelona 08035 Spain Details
ArriVent Investigative Site Madrid 28033 Spain Details
ArriVent Investigative Site Madrid 28050 Spain Details
ArriVent Investigative Site Valencia 46026 Spain Details
ArriVent Investigative Site London NW12PG United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field